Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TM4SF1-directed chimeric antigen receptor T cells
- Development stage
- Phase 1
- Lead developer
- The First Affiliated Hospital of Zhengzhou University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TM4SF1-directed chimeric antigen receptor T cells (CART-TM4SF1) are an investigational cell therapy designed to target Transmembrane 4 L Six Family Member 1 (TM4SF1), a protein highly expressed in various solid tumors, particularly those of the digestive system. TM4SF1 plays a role in cell proliferation, migration, and angiogenesis. These CAR-T cells are typically engineered (some versions as 3rd generation) to recognize TM4SF1-expressing tumor cells and induce targeted cell death. To enhance safety, some constructs incorporate an EGFR-based safety switch, allowing for the depletion of the CAR-T cells if severe toxicity occurs. Clinical evaluation is ongoing for indications including pancreatic, colorectal, gastric, liver, ovarian, and biliary tract cancers.
- Other names
- TM4SF1-targeted CAR-T cellsTM-4SF1-targeted CAR-T cellsTM 4SF1-targeted CAR-T cellsTM4SF1 CAR-TTM-4SF1 CAR-TTM 4SF1 CAR-T
02
Targets
TM4SF1 (Transmembrane 4 L6 family member 1)EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on TM4SF1-directed chimeric antigen receptor T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TM4SF1-directed chimeric antigen receptor T cells.